Vor Biopharma Inc(VOR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 8:21 AM ET (Korea 10/29 21:21)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -83.39 | Insider Own | 45.18% | Shs Outstand | 54.5M | Perf Week | 9.03% |
| Market Cap | 1.22B | Forward P/E | - | EPS next Y | 49.84% | Insider Trans | - | Shs Float | 32.4M | Perf Month | 12.66% |
| Enterprise Value | 0.76B | PEG | - | EPS next Q | -0.84 | Inst Own | 62.58% | Short Float | 22.96% | Perf Quarter | -5.28% |
| Income | 0.63B | P/S | - | EPS this Y | 89.71% | Inst Trans | 20.25% | Short Ratio | 7.85 | Perf Half Y | 47.18% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 61.69% | ROA | 182.91% | Short Interest | 7.45M | Perf YTD | 57.87% |
| Book/sh | -3.68 | P/C | 2.62 | EPS past 3/5Y | -14.82% -21.58% | ROE | - | 52W High | -27.95% ($28.66) | Perf Year | -23.31% |
| Cash/sh | 7.88 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 217.69% ($6.50) | Perf 3Y | -50.83% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 69.48% | Gross Margin | - | Volatility(W/M) | 5.95% 6.48% | Perf 5Y | -93.26% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.22 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 19.15 | EPS Q/Q | 99.54% | Profit Margin | - | RSI (14) | 57.79 | Recom | 1.3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.15 | Sales Q/Q | - | SMA20 | 9.21% ($18.91) | Beta | 1.87 | Target Price | $39 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/11 | SMA50 | -1.05% ($20.87) | Rel Volume | 1.07 | Prev Close | $19.54 |
| Employees | 76 | LT Debt/Eq | - | EPS/Sales Surpr. | -64.82% - | SMA200 | 19.54% ($17.27) | Avg Volume(3M) | 0.95M | Price | $20.65 |
| IPO | 2021/2/5 | Option/Short | Yes/Yes | Trades | 7273 | Volume | 1,013,858 | Change | 5.68% |
🧬 Boher BioPharma is a US-based clinical-stage biotech company. It initially developed cell and gene therapies for hematologic cancers, but has recently shifted the focus of its pipeline toward antibody-based candidates targeting autoimmune diseases. It is classified as a growth-oriented biotech company centered on drug development, with no material commercial revenue yet.
Over the past 1 year, roughly in the middle
28% below its 1-year high.
Traded about as much as usual. That is 107% of its average volume.
VOR earns at a steady pace
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +89.7% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
23.0% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #144 of 594 in the industry
Based on market cap of $1B.
FAQ
What kind of company is VOR?
VOR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VOR?
The market cap of VOR is approximately $1.2B, ranking 2,440 within its sector.
What is the 52-week high and low for VOR?
VOR has recorded a 52-week high of $28.66 and a low of $6.50.
